Dr. Witzig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-0527- Is this information wrong?
Summary
- Dr. Thomas Witzig is a hematologist in Rochester, MN and is affiliated with Mayo Clinic Hospital - Rochester. He received his medical degree from University of Illinois College of Medicine and has been in practice 37 years at the Mayo Clinic in Rochester, MN. He is experienced in hematologic oncology (focus lymphoma) and IgG4 related diseases. His lab research is focused on developing new treatments around impairing the DNA damage response in blood cancer cells. He also has a focus on nutrional oncology (Vitamins D, C and Magnesium). He has more than 400 publications.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1982 - 1986
- University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1979 - 1982
- University of Illinois College of MedicineClass of 1979
Certifications & Licensure
- MN State Medical License 1982 - 2025
- IA State Medical License 1979 - 1982
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Start of enrollment: 1998 Feb 01
- Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy Start of enrollment: 1998 Dec 01
- Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 1999 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy.Jessica F Burlile, Kelsey M Frechette, William G Breen, Steven R Hwang, Alexandra S Higgins, Adrienne N Nedved, William S Harmsen, Sydney D Pulsipher, Thomas E Witzig,...> ;Blood Advances. 2024 Mar 12
- Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar> ;Leukemia. 2024 Feb 28
- Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma.Truong, H., Barreto, J., Mara, K., Hampel, P., Micallef, I., Nowakowski, G., Thanarajasingam, G., Thompson, C., Wang, Y., Witzig, T., Herrmann, S., Leung, N.> ;JCO Oncology Practice. 2024 Feb 26
- Join now to see all
Journal Articles
- Primary Systemic Amyloidosis in Patients with Waldenström MacroglobulinemiaAngela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
- Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia CellsRichard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
- Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal LymphomaLisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood
Abstracts/Posters
- Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic LeukemiaThomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic ExperienceThomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients...Thomas E. Witzig, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).2019 ASCO Annual Meeting - 6/1/2019
- Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-cell LymphomaDecember 13th, 2021
- NCI Awards $12.4 Million Lymphoma Research Grant to University of Iowa and Mayo ClinicSeptember 18th, 2017
- Diagnosis of Autoimmune Pancreatitis: The Evolution of Diagnostic Criteria for a Rare DiseaseJune 17th, 2017
- Join now to see all
Grant Support
- P2 - Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2010–2011
- Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2007–2011
- Signal Transduction Inhibitor Therapy For LymphomaNational Cancer Institute2007–2009
- PI3K Pathway Inhibitors For Mantle Cell LymphomaNational Cancer Institute2005–2006
- Enhancement Of Lymphoma Radioimmunotherapy By CPG ODNNational Cancer Institute2002
- Radioimmunotherapy For LymphomaNational Cancer Institute2001–2002
- HematologyNational Cancer Institute2001–2002
- Characterization And Growth Of Clonally Related Myeloma CellNational Cancer Institute2000–2002
- Apoptosis And %S As Prognostic Factors For Colon CancerNational Cancer Institute1998–1999
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Hospital Affiliations
- Mayo Clinic Hospital - RochesterRochester, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: